The overall goals of the CAVR Immunology Core are to provide a centralized resource for analysis of SIV- and SHIV-specific humoral immune responses in serum and mucosal specimens and to standardize the performance of flow cytometric assays that will be carried out by individual laboratories. A comprehensive range of well-standardized and quantitative assays of humoral immunity will be offerered, including a panel of complementary assays for the determination of neutralizing antibody responses and a newly developed assay that provides sensitive and reproducible determination of ADCC activity. To ensure consistent generation of polychromatic flow cytometry data and assays of cell-mediated immunity, the Immunology Core will coordinate the generation of consensus standard operating protocols (SOPs) for immunophenotyping and cytokine flow cytometry (CFC) assays, and supervise the implementation and validation of each SOP at each location.
Specific Aims i nclude: 1. To provide a centralized resource for the analysis of SIV/SHlV-specific antibodies in sera using ELISA and SIV/SHIV neutralization assays;2. To provide a centralized resource for analysis of SIV and SHIV-specific antibody responses in vaginal and rectal secretions;and 3. To ensure standardization of immunophenotyping and ICS assays conducted by different sites through the development of consensus protocols, implementation of proficiency testing, and comparative evaluation of flow cytometric data analysis. These activities will provide a comprehensive and robust assessment of host immune responses elicited by these vaccine approaches and will help define responses that are able to interrupt mucosal transmission of lentiviruses.
Accurate and reproducible analysis of humoral and cellular immune responses is an essential step in the evaluation of candidate AIDS vaccines and efforts to understand mechanisms of immune protection against mucosal infection with SIV or SHIV. The Immunology Core will analyze virus-specific antibody responses in blood and mucosal secretions and ensure that assays conducted at different sites are reproducible and comparable.
|Aid, Malika; Abbink, Peter; Larocca, Rafael A et al. (2017) Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. Cell 169:610-620.e14|
|Barouch, Dan H; Thomas, Stephen J; Michael, Nelson L (2017) Prospects for a Zika Virus Vaccine. Immunity 46:176-182|
|Abbink, Peter; Larocca, Rafael A; Visitsunthorn, Kittipos et al. (2017) Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Sci Transl Med 9:|
|Ackerman, Margaret E; Barouch, Dan H; Alter, Galit (2017) Systems serology for evaluation of HIV vaccine trials. Immunol Rev 275:262-270|
|McMichael, Andrew J; Picker, Louis J (2017) Unusual antigen presentation offers new insight into HIV vaccine design. Curr Opin Immunol 46:75-81|
|Keele, Brandon F; Li, Wenjun; Borducchi, Erica N et al. (2017) Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. Nat Commun 8:15740|
|Zeng, Ming; Smith, Anthony J; Shang, Liang et al. (2016) Mucosal Humoral Immune Response to SIVmac239?nef Vaccination and Vaginal Challenge. J Immunol 196:2809-18|
|Liu, Jinyan; Ghneim, Khader; Sok, Devin et al. (2016) Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science 353:1045-1049|
|Martinez-Navio, José M; Fuchs, Sebastian P; Pedreño-López, Sònia et al. (2016) Host Anti-antibody Responses Following Adeno-associated Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys. Mol Ther 24:76-86|
|Stephenson, Kathryn E; Neubauer, George H; Bricault, Christine A et al. (2016) Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy. Open Forum Infect Dis 3:ofw100|
Showing the most recent 10 out of 52 publications